Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2013 2
2014 7
2015 2
2016 8
2017 4
2018 5
2019 1
2020 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Chae H, Augustin R, Gatineau E, Mayoux E, Bensellam M, Antoine N, Khattab F, Lai BK, Brusa D, Stierstorfer B, Klein H, Singh B, Ruiz L, Pieper M, Mark M, Herrera PL, Gribble FM, Reimann F, Wojtusciszyn A, Broca C, Rita N, Piemonti L, Gilon P. Chae H, et al. Among authors: mayoux e. Mol Metab. 2020 Dec;42:101071. doi: 10.1016/j.molmet.2020.101071. Epub 2020 Sep 5. Mol Metab. 2020. PMID: 32896668 Free PMC article.
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.
Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, Takeda N, Chin-Kanasaki M, Kaneko T, Mayoux E, Mark M, Yanagita M, Ogita H, Araki SI, Maegawa H. Tomita I, et al. Among authors: mayoux e. Cell Metab. 2020 Sep 1;32(3):404-419.e6. doi: 10.1016/j.cmet.2020.06.020. Epub 2020 Jul 28. Cell Metab. 2020. PMID: 32726607 Free article.
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH, Farooq MA, Gaertner S, Bruckert C, Qureshi AW, Lee HH, Benrahla D, Pollet B, Stephan D, Ohlmann P, Lessinger JM, Mayoux E, Auger C, Morel O, Schini-Kerth VB. Park SH, et al. Among authors: mayoux e. Cardiovasc Diabetol. 2020 Feb 18;19(1):19. doi: 10.1186/s12933-020-00997-7. Cardiovasc Diabetol. 2020. PMID: 32070346 Free PMC article.
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD. Verma S, et al. Among authors: mayoux e. JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587. doi: 10.1016/j.jacbts.2018.07.006. eCollection 2018 Oct. JACC Basic Transl Sci. 2018. PMID: 30456329 Free PMC article.
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG. Aroor AR, et al. Among authors: mayoux e. Cardiovasc Diabetol. 2018 Jul 30;17(1):108. doi: 10.1186/s12933-018-0750-8. Cardiovasc Diabetol. 2018. PMID: 30060748 Free PMC article.
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, Welschof P, Kopp M, Gödtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Münzel T, Daiber A. Steven S, et al. Among authors: mayoux e. Redox Biol. 2017 Oct;13:370-385. doi: 10.1016/j.redox.2017.06.009. Epub 2017 Jun 22. Redox Biol. 2017. PMID: 28667906 Free PMC article.
30 results